NOVEL CD38 APPROACH against AGE-RELATED DISEASES:        our products activate autophagy-lysosomal flux and metabolism of CD38+ cells to RESOLVE INFLAMMATION and PROTECT TISSUES 

 

 

 

 

 

ENCEFA, biopharmaceutical company stemming from the Pitié Salpêtrière Hospital (Paris), develops drugs that specifically modulate CD38 (epitope-related), an age-related target, to protect key organs (brain, heart, kidney) in the context of neurodegenerative, metabolic, inflammatory, and more broadly age-related diseases.

 

 

 

 

 

 

 We rescue suffering cells

 

« NC-drugs uniquely act on CD38, an age-related target highly expressed by suffering cells and pro-inflammatory cells (SASP release), to directly

activate their autophagy-lysosomal flux and energy metabolism 

(NAD-independant pathway), while furthermore increasing NAD levels:

an unprecedented mechanism that reinstate health in degenerative cells and act on inflammation resolution »

 

Founders

Laurence BRESSAC

Co-founder, CEO

Chief executive officer, Laurence has more than 15 years of experience in project supervision, consulting, management and SME development. She made the most of her skills in international companies such as DELOITTE. She is always seeking for understanding and improvement.

Damien TOULORGE

Co-founder, CSO

Chief scientific officer, Damien holds a PhD in Cellular Neuroscience from the Brain Institute at the Pitié Saplêtrière Hospital. Prior to join ENCEFA, Damien worked in a consulting firm specialized in life science, and then in another Biotechnology company as neuroscience project manager for experimental biology.

Serge GUERREIRO

Co-founder, CTO

Chief technology officer, Serge is a biotech engineer. His 13 years of experience in molecule research in neuroscience firstly among Pitié Salpétrière laboratory, then Brain Institute at the Pitié Salpêtrière Hospital and then ENCEFA are key. He is at the origin of ENCEFA's discovery and has already contributed to 2 molecules in neuroscience that have been clinically tested.

Origin of our science

Pitiè Salpêtrière Hospital  The Pitiè Salpêtrière University Hospital is a pubic health institution, teaching and research. It is by its size, the leading hospital group in France. Pitié Salpêtrière's services are recognized nationally and often internationally, particularly in reference specialties such as nervous system and mental pathologies, cardiovascular and metabolic pathologies, complex infectious and immune pathologies and many others. 

 

Our supports

 

ENCEFA’s team has the support of international experts, top clinicians, industrial experts with high responsibilities and successful startup managers.

 

Recognized institutions which support Encefa:

 

 

Fight MND, founded in 2014, Australia-based, was established with the purpose of finding effective treatments and ultimately a cure for Motor Neurone Disease. 

 

FightMNDhas invested, in 2021, $970.000 in ENCEFA NC-B8 program against Amyotrophic Lateral Sclerosis. We thank FightMND and the international scientific reviewers for their confidence in the potential of our science, for patients. For additional information, see the release, and the summary of the five drug development projects funded.

 

 

The Muscular Dystrophy Association is a USA-based association of patients, founded in 1950, established for families, by families, with the promise to transform the lives of people living with muscular dystrophy, ALS and related neuromuscular diseases. 

 

 

The National Veterinary School of Alfort is a public institution of higher education and research under the supervision of the Ministry of Agriculture, Food and Forestry. ENVA has a mission of scientific production and research in the field of veterinary sciences, with numerous applications for animal health, human health and environmental protection. Its research objectives are gradually expanding from animal health to public and global health. ENCEFA benefits from an extremely translational approach with ENVA, for this reason we wished to take advantage of their expertise within their research center before proposing our drugs in human clinical trials. 

ENCEFA's two-pager for NEUROPROTECTION in the context of NEURODEGENERATIVE diseases
Encefa Pres 2021 Two-pager NDD.pdf
Document Adobe Acrobat [459.8 KB]

 

 

 

ENCEFA's two-pager for CARDIAC and KIDNEY functions in a context of METABOLIC disorders
Encefa Pres 2021 Two-pager CMD.pdf
Document Adobe Acrobat [312.8 KB]